▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1274 by analyst upside · 2026-11-13
COLL
Collegium Pharmaceutical, Inc.
Healthcare · Market Cap $775M · P/E 22.9x
ANALYST PRICE TARGET
+79.9%
implied upside to consensus target
Current Price $24.95
Consensus Target $44.88
Bull Target $60.0
Bear Target $28.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
5
Hold
1
Sell
0
52-Week Low $21.43
52-Week High $50.79
YTD Return -45.2%
FUNDAMENTALS
Market Cap $775M
P/E Ratio (TTM) 22.9x
Forward P/E 3.5x
EPS (TTM) $1.09
PEG Ratio 0.74
Dividend Yield N/A
Revenue (TTM) $815M
Profit Margin 4.7%
52-WEEK RANGE
52-Week Low $21.43
52-Week High $50.79
Current Price $24.95
Bear Target $28.0
Bull Target $60.0
● Now $24.95 ● Target $44.88
TRADING DATA
Avg Volume 798K
YTD Return -45.2%
Analyst Count 8
Consensus Buy
Upside to Target +79.9%
Last Updated 2026-11-13

ANALYST SUMMARY

Collegium Pharmaceutical, Inc. (COLL) is currently trading at $24.95 with a Wall Street consensus price target of $44.88, implying potential upside of 79.9% over the next 12 months. 8 analysts currently cover COLL, with a consensus rating of Buy - 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $60.0, while the most cautious has a target of $28.0.

COLL operates in the Healthcare sector with a market capitalisation of $775M. The stock is down 45.2% year-to-date and is currently trading near the lower end of its 52-week range of $21.43 – $50.79.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for COLL, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler - Reiterated
Neutral → Neutral 2026-11-06 14% win rate (7 calls)
Needham - Reiterated
Buy → Buy 2026-11-05 20% win rate (5 calls)
Oppenheimer ● Initiated
Outperform 2026-09-23 14% win rate (7 calls)
Truist Securities - Reiterated
Buy → Buy 2026-09-09 Building track record
Leerink Partners ● Initiated
Outperform 2026-09-09 29% win rate (7 calls)
Barclays - Reiterated
Overweight → Overweight 2026-08-19 Building track record
Piper Sandler reit
Neutral → Neutral 2026-08-07 14% win rate (7 calls)
Needham - Reiterated
Buy → Buy 2026-08-06 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
17/30
Consensus clarity
4/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →